SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gefitinib resistance is a significant challenge in treating non-small cell lung cancer (NSCLC), particularly in cases with MET amplification.
• Identifying novel therapeutic agents that can overcome this resistance is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the anticancer effects of SH005S7 on MET-amplified and gefitinib-resistant NSCLC cells (HCC827GR and HCC827).
• To elucidate the molecular mechanisms underlying SH005S7's efficacy, including its impact on cell signaling, proliferation, invasion, and metastasis.
• To evaluate the in vivo efficacy and safety of SH005S7 in a preclinical mouse model.

Main Methods:

• In vitro assays: cell viability, colony formation, anchorage-independent growth, BrdU assay for cell cycle analysis.
• Western blot and immunohistochemistry to assess protein expression and phosphorylation of key signaling molecules (EGFR, HER3, MET, AKT, ERK) and markers of proliferation, invasion, and angiogenesis.
• In vivo studies: oral administration of SH005S7 to nude mice with xenografted human NSCLC tumors, followed by tumor growth assessment and toxicity evaluation (hepatotoxicity, nephrotoxicity).
• Macrophage cytokine release assay (TNF-α) to evaluate immune stimulatory effects.

Main Results:

• SH005S7 demonstrated significant growth inhibitory effects on both HCC827 and HCC827GR cells in vitro.
• SH005S7 inactivated EGFR-related signaling pathways, decreasing phosphorylation of EGFR, HER3, MET, AKT, and ERK.
• The compound inhibited anchorage-independent growth, invasion, and metastasis by downregulating mesenchymal markers (vimentin, snail, MMP-9) and induced cell cycle arrest.
• In vivo, SH005S7 suppressed tumor growth in xenografted mice without causing significant hepatotoxicity or nephrotoxicity.
• Tumor suppression correlated with reduced proliferation, invasiveness, angiogenesis, and decreased signaling pathway activation.
• SH005S7 exhibited immune stimulatory effects on macrophages via TNF-α release without inducing cytotoxicity.

Conclusions:

• SH005S7 effectively inhibits the growth of MET-amplified and gefitinib-resistant NSCLC cells through multi-targeted signaling suppression.
• The drug's ability to overcome gefitinib resistance is linked to its impact on critical oncogenic pathways.
• SH005S7 shows promise as a potential therapeutic agent for NSCLC, with a favorable safety profile and immune-modulatory properties.